In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Viveve Medical Inc (VIVE), with a price target of $4. The company’s shares closed on Friday at $0.49, close to its 52-week low of $0.42.
Yang observed:
“We believe SUI remains the key value driver for the company.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 11.2% and a 43.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Viveve Medical Inc with a $3.50 average price target, a 614.3% upside from current levels. In a report issued on May 10, Maxim Group also reiterated a Buy rating on the stock with a $3 price target.
See today’s analyst top recommended stocks >>
Based on Viveve Medical Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $13.49 million. In comparison, last year the company had a GAAP net loss of $12.67 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Viveve Medical, Inc. engages in the provision of health products. Its activities include development and distribution of women’s health solutions. Its products include non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. The company was founded on March 3, 1987 and is headquartered Englewood, CO.
